首页 | 本学科首页   官方微博 | 高级检索  
     

宫颈癌免疫治疗的耐药机制及应对措施
引用本文:杨钧媛,蔡红兵. 宫颈癌免疫治疗的耐药机制及应对措施[J]. 肿瘤防治研究, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162
作者姓名:杨钧媛  蔡红兵
作者单位:430071 武汉,武汉大学中南医院妇瘤科,湖北省肿瘤医学研究中心,肿瘤生物学行为湖北省重点实验室
摘    要:宫颈癌严重威胁全球女性的生命健康,晚期宫颈癌治疗手段有限,5年生存率不到20%,是妇科肿瘤的巨大挑战。免疫治疗是晚期宫颈癌患者的重要治疗手段之一,包括免疫检查点抑制剂、治疗性疫苗和过继性T细胞免疫疗法等,但免疫治疗耐药性使部分患者无应答而效果不佳。因此,迫切需要深入研究和探讨免疫耐药的机制从而改善耐药,现归纳总结了近年有关宫颈癌中免疫耐药机制的相关研究,主要分为肿瘤内在因素和外在免疫环境改变等因素,并介绍针对免疫耐药提出的应对措施及进展。

关 键 词:宫颈癌  免疫治疗  耐药  免疫逃逸  免疫检查点抑制剂  
收稿时间:2022-02-23

Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer
YANG Junyuan,CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 886-892. DOI: 10.3971/j.issn.1000-8578.2022.22.0162
Authors:YANG Junyuan  CAI Hongbing
Affiliation:Department of Gynecology and Oncology, Zhongnan Hospital of Wuhan University, Hubei Medical Oncology Research Center, Hubei Key Laboratory of Tumor Biological Behavior, Wuhan 430071, China    
Abstract:Cervical cancer has become a serious threat to women's health worldwide, advanced cervical cancer has limited treatment options. 5-year survival rate is less than 20%, which is a huge challenge for the gynecologic oncology community. Immunotherapy is one of the important treatment for patients with advanced cervical cancer. including immune checkpoint inhibitors, therapeutic vaccines, and periprocedural T-cell immunotherapy, etc. However, immunotherapy resistance makes some patients non-responsive and ineffective. Therefore, there is an urgent need to study and explore the mechanism of immune resistance to improve drug resistance. The present review summarizes the relevant studies on the mechanism of immune resistance in cervical cancer in recent years, mainly divided into factors such as intrinsic tumor and altered external immune environment, and introduces the countermeasures and progresses proposed for immune resistance.
Keywords:Cervical cancer   Immunotherapy   Drug resistance   Immune escape   Immune checkpoint inhibitors  
点击此处可从《肿瘤防治研究》浏览原始摘要信息
点击此处可从《肿瘤防治研究》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号